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Overview
Competing risks are events that occur instead of the failure
event of interest, and we cannot treat these as censored
When you have competing events, you want to focus on
cause-speciﬁc hazards rather than standard hazards
When you have competing events, you want to focus on the
cumulative incidence function (CIF) rather than the survival
function
Cox regression is ﬁne for cause-speciﬁc hazards, but for CIFs
you need to go through a lot of work
Competing-risks regression by the method of Fine and Gray
(1999) is a useful alternative
Implemented in the stcrreg command, new to Stata 11
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The problem of competing risks
Deﬁnition
A competing-risk event is an event that impedes what a
researcher actually “wants” to see
For example, if a researcher is interested in recurrence of
breast cancer, cancer occurring in another location would be a
competing event
In general you cannot treat competing events as censored
because
1. The competing events might be dependent, and you usually
can’t test this
2. You are unwilling to apply your results to a counter-factual
world where the competing event doesn’t exist
R. Gutierrez (StataCorp) Competing-risks regression July 15-16, 2010 4 / 26Competing-risks regression
The problem of competing risks
Competing events as censored
What confuses the matter is that, often, it is okay to think of
competing events as censorings. But this is merely a
computational device
That is, the software will often let you treat competing events
as censored, but your interpretation of the results should never
do so
Even more confusing is that some software, such as that for
Kaplan-Meier curves, is not appropriate if you treat competing
events as censored
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Cause-speciﬁc hazards
Breast cancer data
Consider data on 423 women treated for breast cancer
175 women were given an experimental new drug, and the
other 248 women the standard therapy
Time in months until disease progression occurred either at an
old tumor site (local relapse) or at a new site (distant relapse)
was recorded; local relapse is the event of interest
If no event occurred after within 60 months, observations
were censored
Age and race also recorded
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Cause-speciﬁc hazards
Breast cancer data
. use bc_compete, clear
(Breast cancer with competing risks)
. describe
Contains data from bc_compete.dta
obs: 423 Breast cancer with competing risks
vars: 5 13 Jul 2010 04:27
size: 11,844 (99.9% of memory free)
storage display value
variable name type format label variable label
age float %9.0g Age at start of the trial
drug float %9.0g 1 treatment; 0 control
race float %9.0g race 1 white; 2 black; 3 other
time float %9.0g time in months
status float %9.0g 0 censored; 1 local relapse; 2
distant relapse
Sorted by:
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Cause-speciﬁc hazards
Computing-cause speciﬁc hazards
A cause-speciﬁc hazard is the instantaneous risk of failure
from a speciﬁc cause given that failure (from any cause) has
yet to happen
In our example, we have two cause-speciﬁc hazards: one for
local relapse and one for distant relapse
You can estimate, graph, and test a cause-speciﬁc hazard with
“standard” survival software, if you treat the other event as
censored
You need only to modify your interpretation, speciﬁcally, you
need to consider both hazards jointly and not attempt to
disentangle them
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Cause-speciﬁc hazards
Cause-speciﬁc hazard for local relapse
. stset time, failure(status = 1)
(output omitted )
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Cause-speciﬁc hazards
Cause-speciﬁc hazard for distant relapse
. stset time, failure(status = 2)
(output omitted )


















0 20 40 60
analysis time
drug = 0 drug = 1
Smoothed hazard estimates
R. Gutierrez (StataCorp) Competing-risks regression July 15-16, 2010 10 / 26Competing-risks regression
Cause-speciﬁc hazards
Cox regressions for the eﬀect of drug
Because we believe in proportionality of cause-speciﬁc hazards we
can use stcox to test for diﬀerences
. quietly stset time, failure(status = 1)
. stcox drug
Cox regression -- Breslow method for ties
No. of subjects = 423 Number of obs = 423
No. of failures = 135
Time at risk = 15018
LR chi2(1) = 3.85
Log likelihood = -785.18921 Prob > chi2 = 0.0496
_t Haz. Ratio Std. Err. z P>|z| [95% Conf. Interval]
drug .7030953 .1283705 -1.93 0.054 .4915895 1.005601
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Cause-speciﬁc hazards
Cox regressions for the eﬀect of drug
. quietly stset time, failure(status = 2)
. stcox drug
Cox regression -- Breslow method for ties
No. of subjects = 423 Number of obs = 423
No. of failures = 78
Time at risk = 15018
LR chi2(1) = 6.75
Log likelihood = -443.31893 Prob > chi2 = 0.0094
_t Haz. Ratio Std. Err. z P>|z| [95% Conf. Interval]
drug 1.804488 .4120596 2.58 0.010 1.1534 2.823112
Interpretation: Drug treatment somewhat decreases risk of local
relapse while at the same time increasing the risk of distant relapse
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Cumulative incidence functions
Deﬁnition
Despite the ominous name, a CIF is just the probability that
you observe a speciﬁc type of event before a given time
In our analysis, we have two CIFs; one for local relapse and
one for distant relapse
For example, the CIF for local relapse at 5 months is just the
probability of a local relapse before 5 months
CIFs begin at zero at time zero and increase to an upper limit
equal to the eventual probability that the event will take place,
but this is not equal to one because of competing events
Mathematically, the CIF for local relapse is a function of both
cause-speciﬁc hazards
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Cumulative incidence functions
Kaplan-Meier curves
Kaplan-Meier curves are not appropriate for competing risks
. quietly stset time, failure(status = 1)
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Cumulative incidence functions
Kaplan-Meier curves
The previous Kaplan-Meier curve attempts to answer the
question ”What is the probability of no local relapse before
(say) 5 months?”
In a competing-risks setting, a Kaplan-Meier curve is
inadequate for three reasons
First, it fails to acknowledge that local relapse may never
occur. In reality, the probability of local relapse after time
zero is not equal to 1
Second, the Kaplan-Meier calculation does not take into
account dependence between competing events
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Cumulative incidence functions
Kaplan-Meier curves
Third, with competing risks it is better to reverse the
temporal ordering of the question
It makes better sense to ask “What is the probability of local
relapse within 5 months?” than to ask “What is the
probability that nothing happens for the ﬁrst ﬁve months, but
when something does happen I want it to be a local and not a
distant relapse?”
In summary, using Kaplan-Meier demands too much of your
data; it requires independent risks and a world where the
competing event doesn’t occur
As such, you should use the cumulative incidence function
(CIF) instead
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Cumulative incidence functions
Nonparametric estimation
You can estimate CIFs nonparametrically using stcompet, by
Coviello and Boggess (2004) and available from the SSC
. quietly stset time, failure(status = 1)
. stcompet cif = ci, compet1(2) by(drug)
. gen cif_local_drug0 = cif if status == 1 & drug == 0
(333 missing values generated)
. gen cif_local_drug1 = cif if status == 1 & drug == 1
(378 missing values generated)
. twoway line cif_local_* _t, connect(step step) sort
> ytitle(Cumulative Incidence) title(CIF of local relapse)
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The Cox regression approach
Modeling
Nonparametric estimation is ﬂexible, but it cannot adjust for
external covariates such as age and race
Previously we applied Cox regression on drug to both
cause-speciﬁc hazards
These we could then extend to adjust for age and race, at the
cost of the proportionality assumption
We could then use the resulting cause-speciﬁc hazards to
derive estimates of the CIFs
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The Cox regression approach
Tedious, but possible
To calculate a CIF from Cox regression, we need to
1. Predict the baseline hazard contributions from both Cox
regressions on drug, that for local relapse and that for distant
relapse
2. Transform the baseline hazard contributions (which assume
drug == 0) to those for drug == 1 where appropriate
3. Use the hazard contributions to calculate a product limit
estimator of event-free survival for both levels of drug
4. Calculate the estimated CIF manually for both drug == 0 and
drug == 1; see page 209 of [ST] for details
5. Plot the results
The point: Assessing covariate eﬀects on the CIF using Cox
regression is a lot of work
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The Cox regression approach
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The Fine and Gray approach (stcrreg)
Modeling the subhazard
An easier way to do CIF covariate analysis is with competing
risks regression, according to the model of Fine and Gray
(1999)
They posit a model for the hazard of the subdistribution for
the failure event of interest, known as the subhazard
Unlike cause-speciﬁc hazards, there is a one-to-one
correspondence between subhazards and CIFs for respective
event types; that is the CIF for local relapse is a function of
only the subhazard for local relapse
Covariates aﬀect the subhazard proportionally, similar to Cox
regression
You do this in Stata 11 using stcrreg. stcurve after
stcrreg will plot comparative CIFs for you
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The Fine and Gray approach (stcrreg)
Using stcrreg
. quietly stset time, failure(status = 1)
. stcrreg drug, compete(status = 2)
Competing-risks regression No. of obs = 423
No. of subjects = 423
Failure event : status == 1 No. failed = 135
Competing event: status == 2 No. competing = 78
No. censored = 210
Wald chi2(1) = 4.68
Log pseudolikelihood = -794.95545 Prob > chi2 = 0.0305
Robust
_t SHR Std. Err. z P>|z| [95% Conf. Interval]
drug .6810812 .1209317 -2.16 0.031 .4809068 .9645769
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The Fine and Gray approach (stcrreg)
stcurve after stcrreg
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Concluding remarks
Competing risks are events that prevent an event of interest
from occurring
If you have competing risks, you want to look at
cause-speciﬁc hazards instead of standard hazards
If you have competing risks, you want to look at CIFs instead
of survival functions
CIF analysis with Cox regression is possible, but diﬃcult
stcrreg followed by stcurve is the easier way to go
Keep in mind, however, that easier does not mean correct.
There are model assumptions to be made for either of the two
approaches
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